Connected Therapy
Delivering clinical benefits with solid efficacy1
Targeted
Pulmonary selectivity2
A tolerable safety profile with minimal systemic effects1,3,4
Rapid
Fast-acting4
Patients may feel the benefit in minutes4
Well-established
Proven efficacy2,5
The benefit is sustained long-term5
Versatile
Low interaction potential6
A potential partner for other types of pulmonary hypertension treatments7-9
Because the success of treatment depends on its delivery, the Breelib® nebuliser was designed to optimise every aspect of Ventavis® (iloprost trometamol) inhalation10
Breelib uses smart technology for nebulised PAH therapy10
Producing an ultrafine mist11
Ultrafine particle size and density to reach even the finest alveoli12
Nebulising a defined volume10
Ensuring that each breath delivers a controlled amount of Ventavis10
Activated by inhalation10
Putting the patient in control of their dosing, and avoiding waste of Ventavis10,11
Transporting deep to the lungs12
Each breath of Ventavis is followed by a blast of pure air to ensure precise delivery10
Breelib accelerates inhalation, while maintaining tolerability10
While initial plasma concentration is greater than the I-neb®, tolerability is consistent with the known safety profile of inhaled Ventavis10
As limited data points and statistical analysis were available, definitive conclusions cannot be made
The most frequently observed adverse reactions (≥20%) in clinical trials include vasodilatation (including hypotension), headache and cough. The most serious adverse reactions were hypotension, bleeding events, and bronchospasm.10
*The study noted that 96% of eligible patients decided to enter the long-term extension with Breelib despite using the I-Neb before study entry.
Connected Support
Helping patients get the most out of every inhalation10,11
Speed
Enabling rapid
delivery10
Feedback
Guiding inhalation
technique10
Simplicity
Streamlining user
experience10
Connectivity
Providing ongoing
support
Breelib is intuitively designed to easily integrate treatment into everyday life10
Direct feedback guides
the right technique10
Helping the user get the
most out of every breath
Simple to assemble,
replace and maintain11
Minimising the burden of preparation
and maintenance to help treatment feel easy13
Discreet, portable and
easy to use11
Making it easy to use
Breelib on the go14
Sign up for exclusive access to new resources
References
- Krug S et al. Vasc Health Risk Manag 2009; 5(1): 465-74. Return to content
- Olschewski H et al. Ann Intern Med 1996; 124(9): 820-4. Return to content
- Gomberg-Maitland M, Olschewski H. Eur Respir J 2008; 31(4): 891-901. Return to content
- Hill NS et al. Respir Care 2015; 60(6): 794-805. Return to content
- Olschewski H et al. N Eng J Med 2002; 347(5): 322-9. Return to content
- Benza RL et al. J Heart Lung Transplant 2007; 26(5): 437-46. Return to content
- McLaughlin VV et al. Am J Respir Crir Care Med 2006; 174(11): 1257-63. Return to content
- Ghofrani HA et al. J Am Coll Cardiol 2003; 42(1): 158-64. Return to content
- Ghofrani HA et al. N Engl Med J 2013; 369(4): 330-40. Return to content
- Gessler T et al. Pulm Circ 2017; 7(2): 505-13. Return to content
- Breelib Instructions for Use. August 2016. Return to content
- Labiris NR, Dolovich MB. Br J Clin Pharmacol 2003; 56(6): 588-99. Return to content
- Hatley R et al. Eur Respir J 2016; 48: PA4082. Return to content
- Ari A. Eurasian J Pulmonol 2014; 16: 1-7. Return to content
- Ventavis Summary of Product Characteristics. Return to content
Abbreviations
NYHA: New York Heart Association
PH: pulmonary hypertension
Ventavis is indicated for the treatment of adult patients with primary PH, classified as NYHA FC III, to improve exercise capacity and symptoms15
